{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:24:03Z","timestamp":1789503843955,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Italian Ministry of Education University and Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40618-021-01621-5","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T10:02:46Z","timestamp":1624615366000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Human cell-based anti-inflammatory effects of rosiglitazone"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-7278","authenticated-orcid":false,"given":"M.","family":"Sottili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5002-0753","authenticated-orcid":false,"given":"T.","family":"Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-9199","authenticated-orcid":false,"given":"G.","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8150-8177","authenticated-orcid":false,"given":"L.","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-9543","authenticated-orcid":false,"given":"S.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-064X","authenticated-orcid":false,"given":"M.","family":"Luconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7711-0465","authenticated-orcid":false,"given":"A.","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-3114","authenticated-orcid":false,"given":"C.","family":"Crescioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"6494795","DOI":"10.1155\/2017\/6494795","volume":"2017","author":"C Xia","year":"2017","unstructured":"Xia C, Rao X, Zhong J (2017) Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. J Diabetes Res 2017:6494795. https:\/\/doi.org\/10.1155\/2017\/6494795","journal-title":"J Diabetes Res"},{"issue":"2","key":"1621_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.yexcr.2008.10.025","volume":"315","author":"M Sottili","year":"2009","unstructured":"Sottili M, Cosmi L, Borgogni E, Sarchielli E, Maggi L, Francalanci M, Vannelli GB, Ronconi E, Adorini L, Annunziato F, Romagnani P, Serio M, Crescioli C (2009) Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. Exp Cell Res 315(2):264\u2013273. https:\/\/doi.org\/10.1016\/j.yexcr.2008.10.025","journal-title":"Exp Cell Res"},{"issue":"9","key":"1621_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1432-2277.2010.01078.x","volume":"23","author":"C Sagrinati","year":"2010","unstructured":"Sagrinati C, Sottili M, Mazzinghi B, Borgogni E, Adorini L, Serio M, Romagnani P, Crescioli C (2010) Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells. Transpl Int 23(9):914\u2013923. https:\/\/doi.org\/10.1111\/j.1432-2277.2010.01078.x","journal-title":"Transpl Int"},{"issue":"6","key":"1621_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.yexcr.2007.12.016","volume":"314","author":"C Crescioli","year":"2008","unstructured":"Crescioli C, Squecco R, Cosmi L, Sottili M, Gelmini S, Borgogni E, Sarchielli E, Scolletta S, Francini F, Annunziato F, Vannelli GB, Serio M (2008) Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 314(6):1337\u20131350. https:\/\/doi.org\/10.1016\/j.yexcr.2007.12.016","journal-title":"Exp Cell Res"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"4396368","DOI":"10.1155\/2016\/4396368","volume":"2016","author":"R Altara","year":"2016","unstructured":"Altara R, Mallat Z, Booz GW, Zouein FA (2016) The CXCL10\/CXCR3 axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart. J Immunol Res 2016:4396368. https:\/\/doi.org\/10.1155\/2016\/4396368","journal-title":"J Immunol Res"},{"issue":"2","key":"1621_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2265.2006.02723.x","volume":"66","author":"HJ Kim","year":"2007","unstructured":"Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC (2007) Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66(2):282\u2013289. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02723.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1621_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.atherosclerosis.2005.07.001","volume":"186","author":"JP van Wijk","year":"2006","unstructured":"van Wijk JP, Cabezas MC, Coll B, Joven J, Rabelink TJ, de Koning EJ (2006) Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. Atherosclerosis 186(1):152\u2013159. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2005.07.001","journal-title":"Atherosclerosis"},{"issue":"24","key":"1621_CR8","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457\u20132471. https:\/\/doi.org\/10.1056\/NEJMoa072761","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1621_CR9","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc20-S010","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association (2020) Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care 43(Suppl 1):S111\u2013S134. https:\/\/doi.org\/10.2337\/dc20-S010","journal-title":"Diabetes Care"},{"issue":"3","key":"1621_CR10","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10753-016-0359-6","volume":"39","author":"L Di Luigi","year":"2016","unstructured":"Di Luigi L, Corinaldesi C, Colletti M, Scolletta S, Antinozzi C, Vannelli GB, Giannetta E, Gianfrilli D, Isidori AM, Migliaccio S, Poerio N, Fraziano M, Lenzi A, Crescioli C (2016) Phosphodiesterase type 5 inhibitor sildenafil decreases the proinflammatory chemokine CXCL10 in human cardiomyocytes and in subjects with diabetic cardiomyopathy. Inflammation 39(3):1238\u20131252. https:\/\/doi.org\/10.1007\/s10753-016-0359-6","journal-title":"Inflammation"},{"issue":"4","key":"1621_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.biomag.2011.07.001","volume":"2","author":"S Scolletta","year":"2012","unstructured":"Scolletta S, Buonamano A, Sottili M, Giomarelli P, Bonizella B, Vannelli GB, Serio M, Romagnani P, Crescioli C (2012) CXCL10 release in cardiopulmonary bypass: an in vivo and in vitro study. Biomed Aging Pathol 2(4):187\u2013194. https:\/\/doi.org\/10.1016\/j.biomag.2011.07.001","journal-title":"Biomed Aging Pathol"},{"issue":"6","key":"1621_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40618-018-0977-y","volume":"42","author":"S Giannattasio","year":"2019","unstructured":"Giannattasio S, Corinaldesi C, Colletti M, Di Luigi L, Antinozzi C, Filardi T, Scolletta S, Basili S, Lenzi A, Morano S, Crescioli C (2019) The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence. J Endocrinol Invest 42(6):715\u2013725. https:\/\/doi.org\/10.1007\/s40618-018-0977-y","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1621_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00011-004-1298-5","volume":"53","author":"NG Frangogiannis","year":"2004","unstructured":"Frangogiannis NG (2004) Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res 53(11):585\u2013595. https:\/\/doi.org\/10.1007\/s00011-004-1298-5","journal-title":"Inflamm Res"},{"key":"1621_CR14","doi-asserted-by":"publisher","unstructured":"Birks EJ, Burton PB, Owen V, Mullen AJ, Hunt D, Banner NR, Barton PJ, Yacoub MH (2000) Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 102 (19 Suppl 3):III352\u2013358. https:\/\/doi.org\/10.1161\/01.cir.102.suppl_3.iii-352","DOI":"10.1161\/01.cir.102.suppl_3.iii-352"},{"key":"1621_CR15","doi-asserted-by":"publisher","unstructured":"Liotta F, Frosali F, Querci V, Mantei A, Fili L, Maggi L, Mazzinghi B, Angeli R, Ronconi E, Santarlasci V, Biagioli T, Lasagni L, Ballerini C, Parronchi P, Scheffold A, Cosmi L, Maggi E, Romagnani S, Annunziato F (2008) Human immature myeloid dendritic cells trigger a TH2-polarizing program via Jagged-1\/Notch interaction. J Allergy Clin Immunol 121 (4):1000\u20131005 e1008. https:\/\/doi.org\/10.1016\/j.jaci.2008.01.004","DOI":"10.1016\/j.jaci.2008.01.004"},{"issue":"7","key":"1621_CR16","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1210\/en.2008-0078","volume":"149","author":"E Borgogni","year":"2008","unstructured":"Borgogni E, Sarchielli E, Sottili M, Santarlasci V, Cosmi L, Gelmini S, Lombardi A, Cantini G, Perigli G, Luconi M, Vannelli GB, Annunziato F, Adorini L, Serio M, Crescioli C (2008) Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology 149(7):3626\u20133634. https:\/\/doi.org\/10.1210\/en.2008-0078","journal-title":"Endocrinology"},{"issue":"1","key":"1621_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1677\/JOE-07-0240","volume":"195","author":"C Crescioli","year":"2007","unstructured":"Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, Mazzinghi B, Francalanci M, Pezzatini A, Perigli G, Vannelli GB, Annunziato F, Serio M (2007) Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 195(1):145\u2013155. https:\/\/doi.org\/10.1677\/JOE-07-0240","journal-title":"J Endocrinol"},{"issue":"4","key":"1621_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/01.RES.0000177670.72216.9b","volume":"97","author":"P Romagnani","year":"2005","unstructured":"Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, Cosmi L, Maggi L, Lasagni L, Scheffold A, Kruger M, Dimmeler S, Marra F, Gensini G, Maggi E, Romagnani S (2005) CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 97(4):314\u2013322. https:\/\/doi.org\/10.1161\/01.RES.0000177670.72216.9b","journal-title":"Circ Res"},{"issue":"3","key":"1621_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.urolonc.2010.05.009","volume":"30","author":"F Malentacchi","year":"2012","unstructured":"Malentacchi F, Vinci S, Della Melina A, Kuncova J, Villari D, Giannarini G, Nesi G, Selli C, Orlando C (2012) Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments. Urol Oncol 30(3):278\u2013284. https:\/\/doi.org\/10.1016\/j.urolonc.2010.05.009","journal-title":"Urol Oncol"},{"issue":"10","key":"1621_CR20","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1210\/jc.2002-021949","volume":"88","author":"M Mannelli","year":"2003","unstructured":"Mannelli M, Ferruzzi P, Luciani P, Crescioli C, Buci L, Corona G, Serio M, Peri A (2003) Cushing\u2019s syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. J Clin Endocrinol Metab 88(10):4616\u20134622. https:\/\/doi.org\/10.1210\/jc.2002-021949","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1621_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"6042162","DOI":"10.1155\/2016\/6042162","volume":"2016","author":"L Fang","year":"2016","unstructured":"Fang L, Zhang M, Li Y, Liu Y, Cui Q, Wang N (2016) PPARgene: a database of experimentally verified and computationally predicted PPAR target genes. PPAR Res 2016:6042162. https:\/\/doi.org\/10.1155\/2016\/6042162","journal-title":"PPAR Res"},{"issue":"4","key":"1621_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010100","volume":"5","author":"V Salomaa","year":"2010","unstructured":"Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K, Blankenberg S (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5(4):e10100. https:\/\/doi.org\/10.1371\/journal.pone.0010100","journal-title":"PLoS ONE"},{"issue":"7","key":"1621_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2337\/dc08-1935","volume":"32","author":"JA Kolberg","year":"2009","unstructured":"Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O, Borch-Johnsen K (2009) Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 32(7):1207\u20131212. https:\/\/doi.org\/10.2337\/dc08-1935","journal-title":"Diabetes Care"},{"issue":"6","key":"1621_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019852","volume":"6","author":"C Herder","year":"2011","unstructured":"Herder C, Baumert J, Zierer A, Roden M, Meisinger C, Karakas M, Chambless L, Rathmann W, Peters A, Koenig W, Thorand B (2011) Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA\/KORA Augsburg case-cohort study. PLoS ONE 6(6):e19852. https:\/\/doi.org\/10.1371\/journal.pone.0019852","journal-title":"PLoS ONE"},{"issue":"9","key":"1621_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1161\/01.ATV.0000235691.84430.86","volume":"26","author":"C Herder","year":"2006","unstructured":"Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, Koenig W (2006) Chemokines and incident coronary heart disease: results from the MONICA\/KORA Augsburg case-cohort study, 1984\u20132002. Arterioscler Thromb Vasc Biol 26(9):2147\u20132152. https:\/\/doi.org\/10.1161\/01.ATV.0000235691.84430.86","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1621_CR27","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.2741\/3074","volume":"13","author":"CB Guest","year":"2008","unstructured":"Guest CB, Park MJ, Johnson DR, Freund GG (2008) The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 13:5187\u20135194. https:\/\/doi.org\/10.2741\/3074","journal-title":"Front Biosci"},{"issue":"2","key":"1621_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejcb.2011.09.011","volume":"91","author":"C Crescioli","year":"2012","unstructured":"Crescioli C, Sottili M, Bonini P, Cosmi L, Chiarugi P, Romagnani P, Vannelli GB, Colletti M, Isidori AM, Serio M, Lenzi A, Di Luigi L (2012) Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol 91(2):139\u2013149. https:\/\/doi.org\/10.1016\/j.ejcb.2011.09.011","journal-title":"Eur J Cell Biol"},{"issue":"17\u201318","key":"1621_CR29","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.cca.2012.02.009","volume":"413","author":"P Romagnani","year":"2012","unstructured":"Romagnani P, Crescioli C (2012) CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 413(17\u201318):1364\u20131373. https:\/\/doi.org\/10.1016\/j.cca.2012.02.009","journal-title":"Clin Chim Acta"},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"10096","DOI":"10.1038\/srep10096","volume":"5","author":"CC Chang","year":"2015","unstructured":"Chang CC, Wu CL, Su WW, Shih KL, Tarng DC, Chou CT, Chen TY, Kor CT, Wu HM (2015) Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Sci Rep 5:10096. https:\/\/doi.org\/10.1038\/srep10096","journal-title":"Sci Rep"},{"issue":"5","key":"1621_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/met.2012.0045","volume":"10","author":"SK Jain","year":"2012","unstructured":"Jain SK, Kahlon G, Morehead L, Lieblong B, Stapleton T, Hoeldtke R, Bass PF 3rd, Levine SN (2012) The effect of sleep apnea and insomnia on blood levels of leptin, insulin resistance, IP-10, and hydrogen sulfide in type 2 diabetic patients. Metab Syndr Relat Disord 10(5):331\u2013336. https:\/\/doi.org\/10.1089\/met.2012.0045","journal-title":"Metab Syndr Relat Disord"},{"issue":"1\u20132","key":"1621_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7754\/clin.lab.2012.120225","volume":"59","author":"SM Sajadi","year":"2013","unstructured":"Sajadi SM, Khoramdelazad H, Hassanshahi G, Rafatpanah H, Hosseini J, Mahmoodi M, Arababadi MK, Derakhshan R, Hasheminasabzavareh R, Hosseini-Zijoud SM, Ahmadi Z (2013) Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: evidence for the involvement of inflammation and angiogenesis\/angiostasis in this disease state. Clin Lab 59(1\u20132):133\u2013137. https:\/\/doi.org\/10.7754\/clin.lab.2012.120225","journal-title":"Clin Lab"},{"key":"1621_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/893106","volume":"2014","author":"P van den Borne","year":"2014","unstructured":"van den Borne P, Quax PH, Hoefer IE, Pasterkamp G (2014) The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res Int 2014:893106. https:\/\/doi.org\/10.1155\/2014\/893106","journal-title":"Biomed Res Int"},{"key":"1621_CR34","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3389\/fimmu.2018.01932","volume":"9","author":"V Szentes","year":"2018","unstructured":"Szentes V, Gazdag M, Szokodi I, Dezsi CA (2018) The role of CXCR3 and associated chemokines in the development of atherosclerosis and during myocardial infarction. Front Immunol 9:1932. https:\/\/doi.org\/10.3389\/fimmu.2018.01932","journal-title":"Front Immunol"},{"issue":"4","key":"1621_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12265-016-9703-3","volume":"9","author":"R Altara","year":"2016","unstructured":"Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, Staessen JA, Struijker-Boudier HA, Booz GW, Blankesteijn WM (2016) CXCL10 Is a circulating inflammatory marker in patients with advanced heart failure: a pilot study. J Cardiovasc Transl Res 9(4):302\u2013314. https:\/\/doi.org\/10.1007\/s12265-016-9703-3","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"1621_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003688","volume":"10","author":"SS Bansal","year":"2017","unstructured":"Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD (2017) Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail 10(3):e003688. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003688","journal-title":"Circ Heart Fail"},{"key":"1621_CR37","doi-asserted-by":"publisher","unstructured":"Filardi T, Ghinassi B, Di Baldassarre A, Tanzilli G, Morano S, Lenzi A, Basili S, Crescioli C (2019) Cardiomyopathy associated with diabetes: the central role of the cardiomyocyte. Int J Mol Sci 20 (13). https:\/\/doi.org\/10.3390\/ijms20133299","DOI":"10.3390\/ijms20133299"},{"issue":"21","key":"1621_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.113.007101","volume":"129","author":"F Laroumanie","year":"2014","unstructured":"Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C, Delage C, Calise D, Dutaur M, Parini A, Pizzinat N (2014) CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation 129(21):2111\u20132124. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.007101","journal-title":"Circulation"},{"issue":"4","key":"1621_CR39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","volume":"8","author":"T Nevers","year":"2015","unstructured":"Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velazquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcaide P (2015) Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail 8(4):776\u2013787. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002225","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1621_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/CIRCRESAHA.115.303895","volume":"115","author":"J Weirather","year":"2014","unstructured":"Weirather J, Hofmann UD, Beyersdorf N, Ramos GC, Vogel B, Frey A, Ertl G, Kerkau T, Frantz S (2014) Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte\/macrophage differentiation. Circ Res 115(1):55\u201367. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.303895","journal-title":"Circ Res"},{"issue":"4","key":"1621_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1155\/2013\/931915","volume":"35","author":"F Mahmoud","year":"2013","unstructured":"Mahmoud F, Al-Ozairi E (2013) Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes. Dis Markers 35(4):235\u2013241. https:\/\/doi.org\/10.1155\/2013\/931915","journal-title":"Dis Markers"},{"key":"1621_CR42","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1100\/tsw.2006.179","volume":"6","author":"JF Navarro","year":"2006","unstructured":"Navarro JF, Mora C (2006) Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. Sci World J 6:908\u2013917. https:\/\/doi.org\/10.1100\/tsw.2006.179","journal-title":"Sci World J"},{"key":"1621_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fendo.2019.00315","volume":"10","author":"JA Spanier","year":"2019","unstructured":"Spanier JA, Tse HM, Horwitz MS, Fife BT (2019) Editorial: fresh ideas, foundational experiments: immunology and diabetes. Front Endocrinol (Lausanne) 10:315. https:\/\/doi.org\/10.3389\/fendo.2019.00315","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1621_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fendo.2014.00126","volume":"5","author":"G Virella","year":"2014","unstructured":"Virella G, Lopes-Virella MF (2014) The role of the immune system in the pathogenesis of diabetic complications. Front Endocrinol (Lausanne) 5:126. https:\/\/doi.org\/10.3389\/fendo.2014.00126","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1621_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ejcb.2010.04.002","volume":"89","author":"G Cantini","year":"2010","unstructured":"Cantini G, Lombardi A, Borgogni E, Francalanci M, Ceni E, Degl\u2019Innocenti S, Gelmini S, Poli G, Galli A, Serio M, Forti G, Luconi M (2010) Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. Eur J Cell Biol 89(9):645\u2013653. https:\/\/doi.org\/10.1016\/j.ejcb.2010.04.002","journal-title":"Eur J Cell Biol"},{"issue":"4","key":"1621_CR46","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/ATVBAHA.107.160713","volume":"28","author":"A Lombardi","year":"2008","unstructured":"Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, Luconi M (2008) A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol 28(4):718\u2013724. https:\/\/doi.org\/10.1161\/ATVBAHA.107.160713","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1621_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13098-019-0432-z","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, Shen X (2019) Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes. Diabetol Metab Syndr 11:35. https:\/\/doi.org\/10.1186\/s13098-019-0432-z","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"1621_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2337\/diacare.27.3.813","volume":"27","author":"JC Pickup","year":"2004","unstructured":"Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27(3):813\u2013823. https:\/\/doi.org\/10.2337\/diacare.27.3.813","journal-title":"Diabetes Care"},{"issue":"2","key":"1621_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cmet.2009.01.003","volume":"9","author":"FT Schulthess","year":"2009","unstructured":"Schulthess FT, Paroni F, Sauter NS, Shu L, Ribaux P, Haataja L, Strieter RM, Oberholzer J, King CC, Maedler K (2009) CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab 9(2):125\u2013139. https:\/\/doi.org\/10.1016\/j.cmet.2009.01.003","journal-title":"Cell Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01621-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T14:15:52Z","timestamp":1641564952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01621-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"13 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human subjects and human fetal tissues were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards; human fetal tissue use was approved by the committee for investigation in humans of the Azienda Ospedaliero-Universitaria Careggi, Florence, Italy (protocol no. 6783\u201304).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all healthy blood donors e tissue donors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This work has been approved for publication by all authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}